'Regulatory considerations' presentation slideshows

CLINICAL DEVELOPMENT OF MARKETED DRUGS FOR NEW USES

CLINICAL DEVELOPMENT OF MARKETED DRUGS FOR NEW USES. RUSSELL KATZ, M.D. DIRECTOR DIVISION OF NEUROLOGY PRODUCTS/CDER. DOMAINS OF INTEREST. Regulatory considerations Pre-clinical/CMC Effectiveness Safety New safety concerns Pediatrics. REGULATORY CONSIDERATIONS.

457 views • 31 slides

PRIVATE PLACEMENTS: From Term Sheets to Offering Materials to Closing

PRIVATE PLACEMENTS: From Term Sheets to Offering Materials to Closing. Leslie A. Drockton, Partner Benesch, Friedlander, Coplan & Aronoff LLP. Overview.

576 views • 19 slides

Dendrimer-based nanotechnology carriers for targeted drug delivery The right drug, to the right place, at the right tim

Dendrimer-based nanotechnology carriers for targeted drug delivery The right drug, to the right place, at the right time. Deborah Ladenheim, PhD Vice President, Regulatory Affairs Avidimer Therapeutics www.avidimer.com. Overview. Requirements for targeted therapeutics

898 views • 10 slides

Dendrimer-based nanotechnology carriers for targeted drug delivery The right drug, to the right place, at the right tim

Dendrimer-based nanotechnology carriers for targeted drug delivery The right drug, to the right place, at the right time. Deborah Ladenheim, PhD Vice President, Regulatory Affairs Avidimer Therapeutics www.avidimer.com. Overview. Requirements for targeted therapeutics

434 views • 10 slides

CoBank Equity Management Tom Houser November 4, 2011

124 views • 10 slides